The established and future biomarkers of malignant pleural mesotheliomaVasiliki Panou, Oluf Dimitri Røe, Mogens Vyberg et al.|Cancer Treatment Reviews|2015Cited by 100
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation StudyAmber Louw, Oluf Dimitri Røe, Vasiliki Panou et al.|Journal of Thoracic Oncology|2022Cited by 65
Non-occupational exposure to asbestos is the main cause of malignant mesothelioma in women in North Jutland, DenmarkVasiliki Panou, Oluf Dimitri Røe, Mogens Vyberg et al.|Scandinavian Journal of Work Environment & Health|2018Cited by 32
Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesotheliomaLouise Andersen Lynggård, Christos Meristoudis, Oluf Dimitri Røe et al.|Journal of the American Society of Cytopathology|2022Cited by 16
Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life settingThomas Ringgaard Petersen, Oluf Dimitri Røe, Vasiliki Panou et al.|Acta Oncologica|2021Cited by 8